These data provide critical proof-of-concept that secondary lymphoid stromal injury repair conferred by AML lysate pulsed DC/CCL21 vaccines can harness the endogenous T cell immune response to eliminate progressive AML without requiring donor lymphocyte infusions or other post-BMT therapies. This evidence concerns the gene CCL21 and acute myeloid leukemia.